GlassScriptPhysician profile
Jesse A Flaxenburg
NPI 1376589242
$6,019.50
in general payments reported to CMS, 2019-2025
37 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $495 · 2021: $434 · 2022: $686 · 2023: $1,080 · 2024: $1,133 · 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,587 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,586.95 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,114.81 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $614.44 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $557.50 | 2019-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $362.20 | 2022-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $326.92 | 2019-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $320.42 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $268.35 | 2022-2025 | Tarpeyo |
| Novo Nordisk INC | $224.23 | 2024-2025 | Rivfloza, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $224.17 | 2019-2025 | |
| Vifor Pharma, INC. | $220.35 | 2019-2025 | Veltassa |
| Travere Therapeutics, INC. | $209.37 | 2019-2025 | |
| Glaxosmithkline, LLC. | $152.40 | 2021-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $138.83 | 2021-2024 | Lupkynis |
| Daiichi Sankyo INC. | $129.94 | 2019-2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $114.00 | 2019 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Flaxenburg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.